Glycoxidation and inflammation in chronic haemodialysis patients

Kalousová, Marta; Sulková, S; Fialová, L; Soukupová, J; Malbohán, I; Špaček, P.; Braun, M.; Mikulíková, L; Fortová, M; Hořejší, M.; Tesař, Vladimı́r; Zima, Tomáš

doi:10.1093/ndt/gfg404

Cited by 49 publications

(38 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2003, we fi rst described elevation of PAPP-A in patients with end-stage renal disease treated with hemodialysis (8) , and subsequently its relationship to renal function (9) and its possible prognostic role in long-term hemodialysis patients (10) . Elevation of PAPP-A measured by a different method with lower reference range was also confi rmed by Coskun et al (11) .…”

Section: History Of Papp-a In Laboratory Medicinementioning

confidence: 99%

“…PAPP-A is present in healthy individuals in very low concentration (6,8) . During normal pregnancy it rises linearly and after labor it disappears from circulation with a half-life of 3 -4 days (31) .…”

Section: Biology Of Papp-a: Gene Structure and Functionmentioning

confidence: 99%

“…In 2003, we fi rst described elevation of PAPP-A in patients with end-stage renal disease treated with hemodialysis (8) . PAPP-A levels are three-fold higher than in healthy controls, however 100 -1000-fold lower than in the fi rst trimester of pregnancy.…”

Section: Clinical and Laboratory Studies In Patients With Kidney Disementioning

confidence: 99%

See 2 more Smart Citations

Pregnancy-associated plasma protein A: spotlight on kidney diseases

Kalousová

Tesař

Muravská

et al. 2012

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Pregnancy-associated plasma protein A (PAPP-A) is a biomarker routinely used in screening for Down syndrome in the fi rst trimester of pregnancy. It is also present in very small amounts in men and non-pregnant women. PAPP-A is a key regulator of local insulin-like growth factor (IGF) bioavailability -IGFs are essential for normal body size during fetal development, but they are associated with aging and agerelated diseases. Measurement of circulating PAPP-A can provide valuable information not only in pregnant women (chromosomal anomalies and adverse pregnancy outcomes) but also in patients with coronary artery disease (contribution to diagnosis, prognostic value) and in patients with kidney diseases. PAPP-A is associated with renal function and proteinuria, is increased mainly in dialysis patients and decreases after kidney transplantation. It is an independent mortality predictor of hemodialysis patients and indicator of adverse outcome of transplanted patients. PAPP-A levels can be infl uenced by various chemicals and drugs, among them mainly heparin. Various assays for PAPP-A exist and the type of assay used in a study should be considered. This article reviews the data summarizing basic information about PAPP-A with a particular focus on the signifi cance of PAPP-A in renal diseases.

show abstract

Section: History Of Papp-a In Laboratory Medicinementioning

confidence: 99%

Section: Biology Of Papp-a: Gene Structure and Functionmentioning

confidence: 99%

See 1 more Smart Citation

Pregnancy-associated plasma protein A: spotlight on kidney diseases

Kalousová

Tesař

Muravská

et al. 2012

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…Glycoxidation products and advanced oxidation protein products show a close relationship with inflammatory markers such as CRP and IL-6 (11)(12)(13). Therefore, the end products of these processes could act as inflammatory markers.…”

Section: Oxidative Stressmentioning

confidence: 99%

Inflammatory Syndrome in Patients on Hemodialysis

Jofre

Rodríguez-Benítez²,

López‐Gómez³

et al. 2006

Journal of the American Society of Nephrology

209

169

View full text Add to dashboard Cite

Mortality is markedly elevated in hemodialysis (HD) patients. Between 30 and 50% of prevalent patients have elevated serum levels of inflammatory markers such as C-reactive protein and IL-6. The presence of inflammation, chronic or episodic, has been found to be associated with increased mortality risk. The causes of inflammation are multifactorial and include patient-related factors, such as underlying disease, comorbidity, oxidative stress, infections, obesity, and genetic or immunologic factors, or on the other side, HD-related factors, mainly depending on the membrane biocompatibility and dialysate quality. The adequate knowledge of these causes and their prevention or treatment if possible may contribute to improving the inflammatory state of patients who are on HD and possibly their mortality.

show abstract

“…[1,3,4] This high cardiovascular mortality is partly explained by an increased prevalence of traditional cardiovascular risk factors, such as hypertension, left ventricular hypertrophy, and low HDL cholesterol. [5][6][7] Other factors directly linked to renal insufficiency also play a role, such as hyperhomocysteinemia, [7] advanced-glycation end products, [8] endothelial dysfunction, [9] and oxidative stress. [10] Among these nontraditional cardiovascular risk factors, high serum phosphorus is a strong predictor of all-cause mortality, and particularly of cardiac mortality.…”

Section: Introductionmentioning

confidence: 99%

Influence of Parathyroidectomy on Mortality in Hemodialysis Patients: A Prospective Observational Study

et al. 2007

View full text Add to dashboard Cite

Background. In hemodialysis patients, the relationships between serum PTH and phosphorus levels and mortality are debated because both high and low turnover bone diseases increase the risk of vascular calcifications. Furthermore, the prevalence of hypoparathyroidism is increasing, and there is a fear that this state is associated with an increase in bone fractures. Methods. We performed a cross-sectional study to determine the prevalence and the causes of hypoparathyroidism (defined as basal and post-hypocalcemic-challenge serum PTH levels < 55 pg/mL) in 97 patients undergoing chronic hemodialysis treatment in our unit. We then prospectively observed patients with low PTH levels (< 55 pg/mL, n=26) and those with hyperparathyroidism defined as a PTH levels > 200 pg/mL (n=25) during eight years for all causes of mortality and bone fractures. Kaplan-Meyer survival curves were adjusted for age and sex. Results. Hypoparathyroidism was present in 30% of our patients. The main causes of hypoparathyroidism were parathyroidectomy (77%) and aluminium and iron overload. Survival did not differ between patients with hypoparathyroidism and hyperparathyroidism and between patients with serum phosphorus < or > 2 mmol/L. Parathyroidectomy was associated with better survival (p < 0.01). Similarly, incidence of bone fractures did not differ for the two groups. Conclusions. Parathyroidectomy is the main cause of hypoparathyroidism in hemodialysis patients and is associated with a lower mortality risk. This result suggests that a more aggressive treatment of secondary hyperparathyroidism could decrease mortality in this high-risk population.

show abstract

Glycoxidation and inflammation in chronic haemodialysis patients

Abstract: Oxidative damage showed a closer relationship to inflammation than advanced glycation (glycoxidation). AOPPs may represent a superior acute biochemical marker, whereas AGEs may better describe chronic long-lasting damage.

Cited by 49 publications

References 16 publications

Pregnancy-associated plasma protein A: spotlight on kidney diseases

Pregnancy-associated plasma protein A: spotlight on kidney diseases

Inflammatory Syndrome in Patients on Hemodialysis

Influence of Parathyroidectomy on Mortality in Hemodialysis Patients: A Prospective Observational Study

Contact Info

Product

Resources

About